Literature DB >> 28669844

Prospective multicentre clinical study on inter- and intrapatient genetic variability for antimicrobial resistance of Helicobacter pylori.

C Bilgilier1, A Stadlmann1, A Makristathis2, J Thannesberger1, M-T Kastner1, P Knoflach3, P Steiner3, M Schöniger-Hekele4, C Högenauer5, A Blesl5, C Datz6, U Huber-Schönauer6, R Schöfl7, F Wewalka7, A Püspök8, N Mitrovits8, J Leiner9, H Tilg10, M Effenberger10, M Moser11, F Siebert12, I Hinterberger12, H Wurzer13, T Stupnicki13, N Watzinger14, G Gombotz14, R Hubmann15, S Klimpel16, S Biowski-Frotz17, C Schrutka-Kölbl18, I Graziadei19, O Ludwiczek19, M Kundi20, A M Hirschl2, C Steininger21.   

Abstract

OBJECTIVES: We report on a large prospective, multicentre clinical investigation on inter- and intrapatient genetic variability for antimicrobial resistance of Helicobacter pylori.
METHODS: Therapy-naive patients (n = 2004) who had undergone routine diagnostic gastroscopy were prospectively included from all geographic regions of Austria. Gastric biopsy samples were collected separately from antrum and corpus. Samples were analysed by histopathology and real-time PCR for genotypic resistance to clarithromycin and quinolones. Clinical and demographic information was analysed in relation to resistance patterns.
RESULTS: H. pylori infection was detected in 514 (26%) of 2004 patients by histopathology and confirmed in 465 (90%) of 514 patients by real-time PCR. PCR results were discordant for antrum and corpus in 27 (5%) of 514 patients, indicating inhomogeneous infections. Clarithromycin resistance rates were 17% (77/448) and 19% (84/455), and quinolone resistance rates were 12% (37/310) and 10% (32/334) in antrum and corpus samples, respectively. Combination of test results per patient yielded resistance rates of 21% (98/465) and 13% (50/383) for clarithromycin and quinolones, respectively. Overall, infection with both sensitive and resistant H. pylori was detected in 65 (14%) of 465 patients.
CONCLUSIONS: Anatomically inhomogeneous infection with different, multiple H. pylori strains is common. Prospective clinical study design, collection of samples from multiple sites and microbiologic methods that allow the detection of coinfections are mandatory for collection of reliable data on antimicrobial resistance patterns in representative patient populations. (ClinicalTrials.gov identifier: NCT02925091).
Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial resistance; Clarithromycin; Endoscopy; Helicobacter pylori; Heteroresistance; Quinolone

Mesh:

Substances:

Year:  2017        PMID: 28669844     DOI: 10.1016/j.cmi.2017.06.025

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  11 in total

1.  Molecular Detection of Antibiotic-Resistant Helicobacter pylori.

Authors:  Denise Brennan; Colm O'Morain; Deirdre McNamara; Sinéad M Smith
Journal:  Methods Mol Biol       Date:  2021

2.  Development and Validation of Multiplex Quantitative PCR Assay for Detection of Helicobacter pylori and Mutations Conferring Resistance to Clarithromycin and Levofloxacin in Gastric Biopsy.

Authors:  Hasyanee Binmaeil; Alfizah Hanafiah; Isa Mohamed Rose; Raja Affendi Raja Ali
Journal:  Infect Drug Resist       Date:  2021-10-06       Impact factor: 4.003

3.  A multicenter prospective study on the diagnostic performance of a new liquid rapid urease test for the diagnosis of Helicobacter pylori infection.

Authors:  Werner Dolak; Ceren Bilgilier; Alexander Stadlmann; Judith Leiner; Andreas Püspök; Wolfgang Plieschnegger; Franz Siebert; Friedrich Wewalka; Rainer Schöfl; Ursula Huber-Schönauer; Christian Datz; Susanne Biowski-Frotz; Christoph Högenauer; Christiane Schrutka-Kölbl; Athanasios Makristathis; Maximilian Schöniger-Hekele; Christoph Steininger
Journal:  Gut Pathog       Date:  2017-12-22       Impact factor: 4.181

4.  The Human Gastric Microbiome Is Predicated upon Infection with Helicobacter pylori.

Authors:  Ingeborg Klymiuk; Ceren Bilgilier; Alexander Stadlmann; Jakob Thannesberger; Marie-Theres Kastner; Christoph Högenauer; Andreas Püspök; Susanne Biowski-Frotz; Christiane Schrutka-Kölbl; Gerhard G Thallinger; Christoph Steininger
Journal:  Front Microbiol       Date:  2017-12-14       Impact factor: 5.640

5.  Prevalence of Helicobacter pylori and its CagA subtypes in gastric cancer and duodenal ulcer at an Austrian tertiary referral center over 25 years.

Authors:  Yumiko Kamogawa-Schifter; Yoshio Yamaoka; Tomohisa Uchida; Andrea Beer; Barbara Tribl; Maximilian Schöniger-Hekele; Michael Trauner; Werner Dolak
Journal:  PLoS One       Date:  2018-05-29       Impact factor: 3.240

6.  Plasmid DNA contaminant in molecular reagents.

Authors:  N Wally; M Schneider; J Thannesberger; M T Kastner; T Bakonyi; S Indik; T Rattei; J Bedarf; F Hildebrand; J Law; J Jovel; C Steininger
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

7.  Comparison of the Diagnostic Performance of qPCR, Sanger Sequencing, and Whole-Genome Sequencing in Determining Clarithromycin and Levofloxacin Resistance in Helicobacter pylori.

Authors:  Konrad Egli; Karoline Wagner; Peter M Keller; Lorenz Risch; Martin Risch; Thomas Bodmer
Journal:  Front Cell Infect Microbiol       Date:  2020-12-17       Impact factor: 5.293

8.  Helicobacter pylori Antimicrobial Resistance and Gene Variants in High- and Low-Gastric-Cancer-Risk Populations.

Authors:  Anthony Mannion; JoAnn Dzink-Fox; Zeli Shen; M Blanca Piazuelo; Keith T Wilson; Pelayo Correa; Richard M Peek; M Constanza Camargo; James G Fox
Journal:  J Clin Microbiol       Date:  2021-04-20       Impact factor: 5.948

9.  Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection.

Authors:  Jeemyoung Kim; Eun Jeong Gong; Myeongsook Seo; Hyun Il Seo; Jong Kyu Park; Sang Jin Lee; Koon Hee Han; Woo Jin Jeong; Young Don Kim; Gab Jin Cheon
Journal:  J Pers Med       Date:  2022-01-06

10.  Efficacy of Clarithromycin Depends on the Bacterial Density in Clarithromycin-Heteroresistant Helicobacter pylori Infections: An In Situ Detected Susceptibility and Quantitative Morphometry-Based Retrospective Study.

Authors:  Jewel Ju Ea Kim; Ildikó Kocsmár; György Miklós Buzás; Ildikó Szirtes; Orsolya Rusz; Csaba Diczházi; Attila Szijártó; István Hritz; Zsuzsa Schaff; András Kiss; Éva Kocsmár; Gábor Lotz
Journal:  Pathol Oncol Res       Date:  2021-06-29       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.